---
layout: post
title: "Regulatory Considerations for Prescription Drug Use-Related Software; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:56:52 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-20241
original_published: 2023-09-19 00:00:00 +0000
significance: 8.00
---

# Regulatory Considerations for Prescription Drug Use-Related Software; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 19, 2023 00:00 UTC
**Document Number:** 2023-20241

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Regulatory Considerations for Prescription Drug Use-Related Software." This draft guidance describes FDA's application of its drug labeling authorities to certain software outputs that are disseminated by or on behalf of a drug sponsor for use with a prescription drug or a prescription drug- led, drug-device combination product, which is assigned to the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research as the lead center.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/19/2023-20241/regulatory-considerations-for-prescription-drug-use-related-software-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-20241

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
